SCHEDULE: RA Capital Management Discloses 12.3% Stake in Adicet Bio

RA Capital Management, along with its affiliates, has reported beneficial ownership of 12.3% of Adicet Bio's common stock, totaling 1,182,624 shares, as of February 17, 2026.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. have collectively disclosed beneficial ownership of 1,182,624 shares of Adicet Bio, Inc. common stock.
• This holding represents 12.3% of the company's outstanding common stock.
• The filing is an amendment (Amendment No. 3) to a Schedule 13G.
• The reporting persons are investment advisers and investment companies.
• The Fund holds pre-funded warrants exercisable for up to 1,152,833 shares, but is currently prohibited from exercising them due to a beneficial ownership blocker provision that limits ownership to 9.99%.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily a disclosure of existing ownership and potential future share acquisition limitations, rather than an indicator of immediate positive or negative performance.

Positives

• Significant stake held by a major investment firm (RA Capital Management) indicates confidence or strategic interest in Adicet Bio.
• The reporting persons are sophisticated investors, suggesting a thorough due diligence process.
• The filing clarifies ownership structure and voting/dispositive power delegation.

Negatives

• The Fund is currently unable to exercise its pre-funded warrants due to a beneficial ownership blocker, limiting potential future share acquisition.
• The disclaimers of beneficial ownership by the Fund, RA Capital, Dr. Kolchinsky, and Mr. Shah, except for determining Section 13(d) obligations, suggest a complex ownership and control structure.

Risks

• The beneficial ownership blocker on the pre-funded warrants limits the Fund's ability to increase its stake beyond 9.99% without triggering restrictions.
• Potential for future changes in beneficial ownership or voting power, as indicated by the disclaimers and delegation of power.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Adicet Bio. However, the presence of pre-funded warrants suggests potential future share issuances, contingent on the beneficial ownership blocker provisions.

Management Comments

• The Reporting Persons expressly disclaim status as a 'group' for purposes of this Schedule 13G/A.
• The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund's portfolio, including the shares of the Issuer's common stock reported herein.
• Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days' notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act.
• As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital.
• RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G/A other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G/A shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

Industry Context

StockSavvy.ai notes that significant stake disclosures by investment firms like RA Capital Management often signal active engagement or a strategic view on a company's prospects within the biotechnology sector, particularly for companies focused on novel therapeutics.

Stakeholder Impact

• Shareholders: The disclosure confirms a significant institutional investor's stake, which can influence market perception and potentially stock liquidity. The limitations on warrant exercise may affect future dilution expectations.
• Management: The filing clarifies the reporting structure and beneficial ownership, impacting corporate governance disclosures.
• Creditors: No direct impact mentioned.

Next Steps

• Monitor future filings from RA Capital Management for any changes in ownership or strategic actions.
• Observe Adicet Bio's performance and corporate developments to understand the rationale behind RA Capital's investment.

Key Dates

Keywords

Adicet Bio, RA Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Pre-funded Warrants, SEC Filing